Japanese ITP patients continue experimental drug in extended safety trial
NCT ID NCT07216079
Summary
This study allows Japanese adults with chronic immune thrombocytopenia (ITP) who benefited from rilzabrutinib in a previous trial to continue taking the oral medication. The main goal is to monitor long-term safety and side effects. Only 4 participants who completed the earlier study and still need ITP treatment are eligible.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number: 1001
Tsuchiura, Ibaraki, 300-0028, Japan
-
Investigational Site Number: 1002
Kanazawa, Ishikawa-ken, 920-8641, Japan
-
Investigational Site Number: 1003
Iruma-gun, Saitama, 350-0495, Japan
Conditions
Explore the condition pages connected to this study.